NCT06651112Recruiting
The ATP Project (Antipsychotic-TEP-Psychosis)
Impacts of Psychosis and Antipsychotics on Cerebral Energy Metabolism: the ATP Project (Antipsychotic-TEP-Psychosis)
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis. The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose). Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 18 (estimated)
- First submitted
- 11 Oct 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Université de Sherbrooke
- Diseases
- Schizophrenia
- NCT number
- NCT06651112
What you commit to
- Study type: Observational
- Planned participants: 18
- From 1 Nov 2024 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal.
- Type 1 diabetes.
- Other conditions that could interfere with participation according to the judgment of the qualified physician.
Other
- Pregnancy, childbirth in the last 6 months, or breastfeeding.
- Presence of a metallic object in the body that is incompatible with MRI.
- Any use of APs for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription).
- Uncontrolled acute suicidal ideation.
Who the study is looking for
- Admission to the PEP clinic in Estrie, either outpatient or inpatient, according to the transdiagnostic PEP model.
- Willingness to begin taking an AP (regardless of type and dose, or change in type and dose during the study).
- Ability to read and express themselves in French or English.
- Capable of understanding and signing consent.
Age in the registry: 18 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hotel-Dieu CIUSSS de l'Estrie-CHUS Coordinator of this site? Confirm its status | Sherbrooke | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.